17,261 trials
Metastatic Renal Cell Carcinoma · Fumarate Hydratase Deficient Renal Cell Carcinoma · Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Primary: the Objective Response Rate (ORR) — 0; 0; 10; 8 Participants
Multiple Sclerosis
Primary: Modulation of One or All Paramagnetic Rim Lesions — .04 proportion of rim lesions modulated
Isolated Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL — 93 percentage of participants
Hypertension
Primary: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM — 6.8; -7.3; -10.0; -8.9 millimeters of mercury (mmHg) — p=<0.0001
Lymphoma, Non-Hodgkin
Primary: Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 — 61.1; 63.0; 70.0 Percent of Participants
Acute Pain
Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of…
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 57.3 Percentage of participants
Heart Failure With Reduced Ejection Fraction (HFrEF) · Low T3 Syndrome
Primary: Cardiac Rhythm Monitoring by 14 Day Patch Rhythm Assessment — 11; 19 Number of participants with events
Foot Pain
Primary: Foot Pain at Its Worst at Baseline and Week 6 — 6.4; 5.3; 3.6; 5.4 unit on scale
Dyslipidemia
Primary: Part B: Change in LDL-C in Serum at Week 12 — 0.198; 0.458; 0.953 Ratio
Glomerulonephritis, Membranous · antiPLA2R Positive
Primary: Number of Participants With Adverse Events — 15; 12 Participants
Cardiac Disease
Primary: 12-lead ECGs — 393.9; 392.0; 386.3; 2.8 millisecond
Aplastic Anemia · Myelodysplastic Syndromes · Fungal Infection
Primary: the Incidence of Proven/Probable/Possible Fungal Infection — 20 Participants
Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 50; 27; 53; 18 Participants
Locally Advanced or Metastatic Renal Cell Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants